reported that 47.3% of endocrinologists opted to repeat FNA in cases of AUS/FLUS (follicular lesion of indeterminate significance), while only 14.1% selected molecular testing due to its limited availability [ 20 ].
← all excerpts
Nationwide web survey on implementing the 2023 ETA guidelines for second-line management thyroid nodules with atypia of undetermined significance.
1
—
—